Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Vaughn Himes Biography and Net Worth

Insider of Seagen

Vaughn has more than 25 years of experience in product development and commercialization at large pharmaceutical and biotechnology companies. With deep operational expertise, he leads manufacturing, supply chain, process sciences, and quality functions for Seagen. Vaughn has played a pivotal role in the successful commercialization of our marketed products and the development of our robust pipeline of product candidates.

Previously, Vaughn spent 20 years in biotech leadership roles, including as the Senior Vice President of Technical Operations at ZymoGenetics (later acquired by Bristol Myers Squibb), where he oversaw commercial and clinical manufacturing, supply chain and logistics, quality control, and process development. Vaughn also spent 10 years in the pharmaceutical industry at Wyeth (now Pfizer).

Vaughn holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.A. in Chemistry from Pomona College.

What is Vaughn B. Himes' net worth?: The estimated net worth of Vaughn B. Himes is at least $9.74 million as of November 9th, 2023. Dr. Himes owns 42,574 shares of Seagen stock worth more than $9,738,377 as of April 26th. This net worth estimate does not reflect any other investments that Dr. Himes may own. Additionally, Dr. Himes receives an annual salary of $1,080,000.00 as Insider at Seagen. Learn More about Vaughn B. Himes' net worth.
How old is Vaughn B. Himes?: Dr. Himes is currently 62 years old. There are 4 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who is 67 years old. Learn More on Vaughn B. Himes' age.
What is Vaughn B. Himes' salary?: As the Insider of Seagen Inc., Dr. Himes earns $1,080,000.00 per year. There are 4 executives that earn more than Dr. Himes. The highest earning executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who commands a salary of $2,480,000.00 per year. Learn More on Vaughn B. Himes' salary.
How do I contact Vaughn B. Himes?: The corporate mailing address for Dr. Himes and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Vaughn B. Himes' contact information.
Has Vaughn B. Himes been buying or selling shares of Seagen?: Vaughn B. Himes has not been actively trading shares of Seagen over the course of the past ninety days. Most recently, Vaughn B. Himes sold 8,785 shares of the business's stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $213.32, for a transaction totalling $1,874,016.20. Following the completion of the sale, the insider now directly owns 42,574 shares of the company's stock, valued at $9,081,885.68. Learn More on Vaughn B. Himes' trading history.
Who are Seagen's active insiders?: Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.
Are insiders buying or selling shares of Seagen?: In the last twelve months, insiders at the biotechnology company sold shares 20 times. They sold a total of 70,520 shares worth more than $14,429,678.66. The most recent insider tranaction occured on November, 10th when CEO David R Epstein sold 10,620 shares worth more than $2,262,166.20. Insiders at Seagen own 25.9% of the company. Learn More about insider trades at Seagen.
Information on this page was last updated on 11/10/2023.

Vaughn B. Himes Insider Trading History at Seagen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/9/2023	Sell	8,785	$213.32	$1,874,016.20	42,574
9/21/2023	Sell	80	$206.50	$16,520.00	51,359
9/7/2023	Sell	8,785	$205.76	$1,807,601.60	51,439
8/31/2023	Sell	1,795	$206.97	$371,511.15	51,439
8/29/2023	Sell	371	$206.00	$76,426.00	53,234
6/7/2023	Sell	16,215	$195.29	$3,166,627.35	43,837
6/17/2022	Sell	1,134	$160.00	$181,440.00	119,471
5/24/2022	Sell	10,866	$136.79	$1,486,360.14	59,064
3/3/2022	Sell	12,000	$127.05	$1,524,600.00
12/20/2021	Sell	345	$149.85	$51,698.25
11/11/2021	Sell	6,000	$178.63	$1,071,780.00
9/8/2021	Sell	6,000	$150.00	$900,000.00
8/16/2021	Sell	658	$154.55	$101,693.90
6/7/2021	Sell	1,303	$150.00	$195,450.00
6/3/2021	Sell	10,697	$144.91	$1,550,102.27	72,894
3/2/2021	Sell	12,000	$153.22	$1,838,640.00
12/7/2020	Sell	8,000	$181.76	$1,454,080.00
9/9/2020	Sell	8,000	$147.55	$1,180,400.00
7/17/2020	Sell	8,000	$179.42	$1,435,360.00	199,840
3/6/2020	Sell	8,000	$114.91	$919,280.00
12/6/2019	Sell	8,000	$117.16	$937,280.00
8/30/2019	Sell	8,000	$72.86	$582,880.00
8/28/2019	Sell	6,836	$73.21	$500,463.56
5/31/2019	Sell	8,000	$65.94	$527,520.00
3/8/2019	Sell	8,000	$68.72	$549,760.00
11/30/2018	Sell	5,000	$62.14	$310,700.00
9/7/2018	Sell	5,000	$76.99	$384,950.00
8/27/2018	Sell	5,530	$74.23	$410,491.90
5/31/2018	Sell	5,000	$58.47	$292,350.00
3/15/2018	Sell	5,000	$58.12	$290,600.00
11/30/2017	Sell	10,000	$59.97	$599,700.00
9/8/2017	Sell	10,000	$53.22	$532,200.00
8/28/2017	Sell	6,377	$47.89	$305,394.53
3/31/2017	Sell	10,000	$62.75	$627,500.00	161,283
12/7/2016	Sell	30,000	$65.32	$1,959,600.00
8/22/2016	Sell	3,991	$46.59	$185,940.69
12/15/2015	Sell	40,500	$39.94	$1,617,570.00	76,212
8/20/2015	Sell	5,997	$42.02	$251,993.94	76,212
11/12/2014	Sell	10,000	$37.52	$375,200.00
6/13/2013	Sell	10,000	$32.11	$321,100.00

Vaughn B. Himes Buying and Selling Activity at Seagen

Seagen Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $228.74

$228.74

50 Day Range

MA: $228.74

$228.74

2 Week Range

Now: $228.74

$123.77

$228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

See why the elites are pouring billions into gold.

Vaughn Himes Biography and Net Worth

What is Vaughn B. Himes' net worth?

How old is Vaughn B. Himes?

What is Vaughn B. Himes' salary?

How do I contact Vaughn B. Himes?

Has Vaughn B. Himes been buying or selling shares of Seagen?

Who are Seagen's active insiders?

Are insiders buying or selling shares of Seagen?